Violence in older persons: Part II - Occurrence in hospitals and pharmacological/behavioral treatment of agitation, aggression, and violence

Clinical Geriatrics

Volumn 16, Issue 6, 2008, Pages 28-32

  Hall, Ryan C W ^a   Hall, Richard C W ^a,b   Chapman, Marcia J ^c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CHOLINESTERASE INHIBITOR; CITALOPRAM; HALOPERIDOL; LORAZEPAM; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; OXAZEPAM; PLACEBO; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; VALPROIC ACID;

AGGRESSION; AGITATION; AKATHISIA; AUTOMUTILATION; BEHAVIOR DISORDER; BEHAVIOR THERAPY; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; COGNITIVE DEFECT; COURT; DELIRIUM; DEMENTIA; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FALLING; FEVER; FORENSIC PSYCHIATRY; GERIATRIC PATIENT; HEALTH CARE PERSONNEL; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HYPOTENSION; LIVER METABOLISM; MEMORY DISORDER; NEUROLEPTIC MALIGNANT SYNDROME; ORTHOSTATIC HYPOTENSION; PERIPHERAL EDEMA; PSYCHOSIS; QT PROLONGATION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SEDATION; SEXUAL MISCONDUCT; SIDE EFFECT; SOMNOLENCE; SYNCOPE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URINARY TRACT DISEASE; VIOLENCE; WITHDRAWAL SYNDROME;

EID: 48149102559     PISSN: 10951598     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Tueth MJ, Zuberi P. Life-threatening psychiatric emergencies in the elderly: Overview. J Geriatr Psychiatry Neurol 1999;12:60-66.
2. Badger F, Mullan B. Aggressive and violent incidents: Perceptions of training and support among staff caring for older people and people with head injury. J Clin Nurs 2004;13:526-533.
3. Love CC, Morrison E; American Academy of Nursing Expert Panel on Violence. American Academy of Nursing Expert Panel on Violence policy recommendations on workplace violence (adopted 2002). Issues Ment Health Nurs 2003;24:599-604.
4. Voyer P, Verreault R, Azizah GM, et al. Prevalence of physical and verbal aggressive behaviours and associated factors among older adults in long-term care facilities. BMC Geriatr 2005;5:13.
5. Ayalon L, Gum AM, Feliciano L, Areán PA. Effectiveness of nonpharmacological interventions for the management of neuropsychiatric symptoms in patients with dementia: A systematic review. Arch Intern Med 2006;166:2182-2188.
6. Henry J, Ginn GO. Violence prevention in healthcare organizations within a total quality management framework. J Nurs Adm 2002;32:479-486.
7. Gates D, Fitzwater E, Succop P. Relationships of stressors, strain, and anger to caregiver assaults. Issues Ment Health Nurs 2003;24:775-793.
8. Kwok RP, Law YK, Li KE, et al. Prevalence of workplace violence against nurses in Hong Kong. Hong Kong Med J 2006;12:6-9.
9. Anderson C. Workplace violence: What factors may be placing you at risk. AWHONN Lifelines 2002;6:212-214.
10. Hegney D, Plank A, Parker V. Workplace violence in nursing in Queensland, Australia: A self-reported study. Int J Nurs Pract 2003;9:261-268.
11. Hegney D, Eley R, Plank A, et al. Workplace violence in Queensland, Australia: The results of a comparative study. Int J Nurs Pract 2006;12:220-231.
12. Esposito NW, Redman RW, Moore KA, et al. Preventing violence in an academic setting: One school of nursing's approach. Nurs Educ Perspect 2005;26:24-28.
13. Lonergan E, Luxenberg J, Colford J. Haloperidol for agitation in dementia. Cochrane Database Syst Rev 2002;(2):CD002852.
14. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: A review of the evidence. JAMA 2005;293:596-608.
15. Hall RC, Appleby B, Hall RC. Atypical neuroleptic malignant syndrome presenting as fever of unknown origin in the elderly. South Med J 2005;98:114-117.
16. Hall RCW, Hall RCW, Chapman M. Neuroleptic malignant syndrome in the elderly: Diagnostic criteria, incidence, risk factors, pathophysiology, and treatment. Clinical Geriatrics 2006;14(5):39-46.
17. Hall RCW, Hall RCW, Chapman M. Central serotonin syndrome: Part II Pathophysiology, drug interactions, and treatment. Clinical Geriatrics 2008;16(1):24-28.
18. Hall RC, Zisook S. Paradoxical reactions to benzodiazepines. Br J Clin Pharmacol 1981;11 Suppl 1:99S-104S.
19. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials. JAMA 2005;294:1934-1943.
20. Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev 2006;(1):CD003476.
21. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: Meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006;14:191-210.
22. Food and Drug Administration. FDA Alert 09/2006. Increased Mortality in Patients with Dementia-Related Psychosis. Available at: http://www.fda.gov/cder/ drug/InfoSheets/HCP/risperidoneHCP.pdf. Accessed March 30, 2008.
23. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005;353:2335-2341.
24. Bies RR, Mulsant BH, Rosen J, et al. Population pharmacokinetics as a method to detect variable risperidone exposure in patients suffering from dementia with behavioral disturbances. Am J Geriatr Pharmacother 2005;3:87-91.
25. De Deyn PP, Katz IR, Brodaty H, et al. Management of agitation, aggression, and psychosis associated with dementia: A pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone. Clin Neurol Neurosurg 2005;107:497-508.
26. Rabinowitz J, Katz IR, De Deyn PP, et al. Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone. J Clin Psychiatry 2004;65:1329-1334.
27. Steinberg M, Sheppard JM, Tschanz JT, et al. The incidence of mental and behavioral disturbances in dementia: The Cache County Study. J Neuropsychiatry Clin Neurosci 2003;15:340-345.
28. Martinon-Torres G, Fioravanti M, Grimley EJ. Trazodone for agitation in dementia. Cochrane Database Syst Rev 2004;(4):CD004990.
29. Lyketsos CG, Steinberg M, Tschanz JT, et al. Mental and behavioral disturbances in dementia: Findings from the Cache County Study on Memory in Aging. Am J Psychiatry 2000;157:708-714.
30. Lyketsos CG, DelCampo L, Steinberg M, et al. Treating depression in Alzheimer disease: Efficacy and safety of sertraline therapy, and the benefits of depression reduction: The DIADS. Arch Gen Psychiatry 2003;60:737-746.
31. Lyketsos CG, Sheppard JM, Steele CD, et al. Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: Initial results from the Depression in Alzheimer's Disease study. Am J Psychiatry 2000;157:1686-1689.
32. Munro CA, Brandt J, Sheppard JM, et al. Cognitive response to pharmacological treatment for depression in Alzheimer disease: Secondary outcomes from the Depression in Alzheimer's disease study (DIADS). Am J Geriatr Psychiatry 2004;12:491-498.
33. Lonergan ET, Cameron M, Luxenberg J. Valproic acid for agitation in dementia. Cochrane Database Syst Rev 2004;(2):CD003945.
34. Porsteinsson AP, Tariot PN, Jakimovich LJ, et al. Valproate therapy for agitation in dementia: Open-label extension of a double-blind trial. Am J Geriatr Psychiatry 2003;11:434-440.
35. Porsteinsson AP, Tariot PN, Erb R, et al. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry 2001;9:58-66.
36. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006;(1):CD005593.
37. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006;(2):CD003154.